Philip Morris International to Present at Chief Executives for Corporate Purpose (CECP) CEO Investor Forum 2023
07 Novembro 2023 - 4:09PM
Business Wire
Regulatory News:
Philip Morris International Inc. (PMI) (NYSE: PM)’s Chief
Executive Officer, Jacek Olczak will hold a presentation and
Q&A session at the CECP CEO Investor Forum 2023 on Tuesday,
November 14, 2023, at 11:00 a.m. ET.
The live video webcast will be available at
www.pmi.com/2023CECP. The presentation slides will also be
available at the same link.
The webcast may also be accessed on mobile devices by
downloading PMI’s Investor Relations App at www.pmi.com/irapp.
Philip Morris International: Delivering a Smoke-Free
Future
Philip Morris International (PMI) is a leading international
tobacco company working to deliver a smoke-free future and evolving
its portfolio for the long term to include products outside of the
tobacco and nicotine sector. The company’s current product
portfolio primarily consists of cigarettes and smoke-free products.
Since 2008, PMI has invested more than USD 10.5 billion to develop,
scientifically substantiate and commercialize innovative smoke-free
products for adults who would otherwise continue to smoke, with the
goal of completely ending the sale of cigarettes. This includes the
building of world-class scientific assessment capabilities, notably
in the areas of pre-clinical systems toxicology, clinical and
behavioral research, as well as post-market studies. In November
2022, PMI acquired Swedish Match – a leader in oral nicotine
delivery – creating a global smoke-free champion led by the
companies’ IQOS and ZYN brands. The U.S. Food and Drug
Administration has authorized versions of PMI’s IQOS Platform 1
devices and consumables and Swedish Match’s General snus as
Modified Risk Tobacco Products. As of September 30, 2023, PMI's
smoke-free products were available for sale in 82 markets, and PMI
estimates that approximately 19.7 million adults around the world
had already switched to IQOS and stopped smoking. Smoke-free
products accounted for approximately 36.2% of PMI’s total
third-quarter 2023 net revenues. With a strong foundation and
significant expertise in life sciences, PMI announced in February
2021 its ambition to expand into wellness and healthcare areas and,
through its Vectura Fertin Pharma business, aims to enhance life
through the delivery of seamless health experiences. For more
information, please visit www.pmi.com and www.pmiscience.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231107938425/en/
Philip Morris International
Investor Relations: Stamford, CT: +1 (203) 905 2413 Lausanne:
+41 (0)58 242 4666 Email: InvestorRelations@pmi.com
Media: David Fraser Lausanne: +41 (0)58 242 4500 Email:
David.Fraser@pmi.com
Philip Morris (NYSE:PM)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Philip Morris (NYSE:PM)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024